Overview

Tiotropium Respimat Pharmacokinetic Study in COPD

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is compare the effect of different doses of tiotropium delivered by the HandiHaler and Respimat device on lung function. Additionally, the study will investigate the pharmacokinetic profile of these different doses. Studying the pharmacokinetic profile shows what happens to the medication in the body over a period of hours and provides information on potential effects of the medication.
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Pharmaceutical Solutions
Tiotropium Bromide